0
No products in the cart.
Cart
Total:
£
0.00
Home
Competencies
Services
Epi Data
Reports
Team
Home
Competencies
Services
Epi Data
Reports
Team
Overview of Kymriah (CAR-T therapy) by Novartis in ALL
£
9.99
Overview of Kymriah (CAR-T therapy) by Novartis in ALL
Add to cart
Category:
digital
Tags:
acute lymphoblastic leukemia
,
acute lymphocytic leukemia
,
CAR-T
,
CAR-T therapy
,
Kymriah
,
Novartis
Share on:
Description
Overview of
Kymriah
(CAR-T therapy) by Novartis in ALL
Slides in the pack:
Kymriah (
tisagenlecleucel)
from Novartis
Pricing
Epidemiology- Acute
Lymphoblastic
Leukemia
(ALL)
Mechanism of action of various treatments for ALL
Other treatments for
acute
lymphoblastic leukemia
Related products
Add to cart
The Atopic Dermatitis market and the approval of Dupixent
£
29.99
Add to cart
Multiple Sclerosis and the launch of Ocrevus
£
29.99
Add to cart
Bladder cancer and immuno-oncology therapies
£
29.99
Add to cart
The impact of Brexit on the pharmaceutical landscape of the United Kingdom
£
9.99